Results were analysed using Wilcoxon's signed rank test. No significant difference was found between either of the paired groups (Table 1) . The data was subsequently plotted to investigate the correlation between the two groups, as shown in Fig. 1 . However, method comparison is more appropriately carried out using the difference plot described by Bland and Altman ( All analyses were performed in duplicate according to the manufacturers suggested protocol.
The following paired samples were analysed:
acidified versus unacidified (n = 20); and acidified versus 'pH corrected' (n = 10). Urine samples were taken from normal subjects and patients suffering from a variety of metabolic bone diseases. Both 24 h and 2 h fasting collections were used.
The concentration and volume of HCI used for sample acidification varies with laboratory. In this study samples were acidified with 10 mL cone HCI irrespective of volume. This ensured the most acidic conditions likely to occur in clinical samples.
Urine samples for pH correction were adjusted to the pH of their unacidified pair using concentrated sodium hydroxide. A volume correction for the addition of alkali was then made.
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We read with interest the evaluation of the Metra Biosystems 'Pyrilinks' assay for free pyridinolines (Metra Biosystems (UK) Ltd, Oxford, UK. Product number 8010) by Hata and Miura. I Their findings are indeed consistent with those of Seyedin.? Delmas" and others" in showing the usefulness of this method in monitoring urinary total free pyridinoline excretion as a marker of bone resorption.
This assay measures free pyridinolines (i.e. pyridinoline and deoxypyridinoline) with 100070 cross-reactivity. Recognition of peptide bound forms of both crosslinks is negligible.
The manufacturer, Hata and Miura, and other authors-? use the abbreviation PYD to represent the sum of both forms of pyridinium crosslink as measured by this method. We feel the use of PYD in this manner leads to a potential fO,r .confusion. It is possible this term may be misinterpreted as indicating either total or free pyridinoline, with no contribution from free deoxypyridinoline to the final result. Although more unwieldy, the term 'total free pyridinolines' is a more accurate description of the compounds measured by this assay.
The prospective use of this assay in the screening and monitoring of patients with osteoporosis and other metabolic bone diseases led us to consider its possible use with 'routine' urine samples.
While it is common in this and many other laboratories to receive urine containing hydrochloric acid (HCI) as a preservative, the assay protocol insists on the use of unpreserved urine. The kit manufacturer has also suggested that acidified urine be 'pH corrected' before assay. We therefore decided to investigate the use of this ELISA with acidified urine samples. Visual inspection of Fig. 2 shows no obvious relationship between the difference in the results and their mean.
The 'outlier' in Fig. 2 (acidified and unacidified values differ by more than 500 nmol/L) represents a 24 h collection from a patient with active Paget's disease. The lower (acidified) pre-treatment result represents a value 15 times the upper limit of the manufacturers quoted reference range as expressed relative to urine creatinine concentration. As such, the difference between these results is unlikely to be clinically significant.
As a post-treatment sample from the same patient showed excellent agreement between acidified and non-acidified samples, it is probable that this discrepancy is due to an analytical error.
CONCLUSION
A more recent assay, measuring free deoxypyridinoline alone, is now available from the same manufacturer ('Pyrilinks-D', Metra Biosystems, UK). Deoxypyridinoline is primarily located in bone collagen, while pyridinoline is also found in cartilage and other soft tissues." The new assay represents a more specific indicator of bone resorption than its predecessor. 7 As the Pyrilinks-D assay involves a lO-fold dilution of urine sample in a phosphate buffer before analysis, it would seem improbable that sample acidification would affect the assay.
The 'Pyrilinks' assay remains available as a general indicator of bone resorption. It may also have applications in other connective tissue disorders, especially those conditions in which the urinary pyridinoline/deoxypyridinoline ratio becomes altered.s-?
We conclude that acidified urine samples are suitable for use in this assay. 
